This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva-Cephalon deal's 'sole explanation' was avoiding competition, EU judges rule

By Nicholas Hirst ( October 23, 2025, 09:41 GMT | Insight) -- Teva Pharmaceuticals has seen top EU judges reject its appeal over a €60.5 million antitrust fine for delaying the launch of a generic drug to challenge Cephalon's blockbuster Modafinil in exchange for a cash payment and other benefits. The EU's lower-tier court had been right to conclude that the “sole explanation” for the companies’ settlement was to avoid competing, the EU Court of Justice said.Teva Pharmaceuticals and rival drugmaker Cephalon breached EU competition rules by agreeing to delay the market entry of a generic drug produced by Teva in exchange for financial benefit, the EU's top court has found....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections